The ANZACS-QI team implemented a pilot heart failure registry in Northern Region hospitals. They used age-stratified random sampling of national administrative datasets to select a representative sample of patients hospitalised with heart failure across 2022 and 2023. Electronic clinical records were reviewed by the study team and data were entered into a web-based registry designed for quality improvement monitoring. The investigators reported a registry form completion rate of 98%, indicating near-complete case capture for the pilot cohort.
The pilot cohort included 328 patients identified through the sampling framework. The registry captured demographic and clinical data from inpatient electronic records, although the abstract does not list detailed patient demographics or comorbidity frequencies. Registry adherence was high, with 98% completion of data collection forms, which supports the feasibility of the chosen workflow and the reliability of the pilot dataset for performance benchmarking.
One of the prespecified performance outcomes analyzed was the rate of left ventricular assessment, specifically documentation of left ventricular ejection fraction (LVEF) within two years of the index hospital discharge. Data indicated that 81% of patients had an LVEF assessment in that two-year window. That majority suggests clinicians are obtaining structural and functional evaluation in most hospitalised patients with heart failure. The abstract does not provide breakdowns by imaging modality, timing relative to admission, or reasons for missing assessments in the remaining 19%.
The investigators examined prescription of guideline-directed medical therapy (GDMT) as a core quality indicator. Among the subgroup with heart failure with reduced ejection fraction who survived to discharge (n=137), only 13 patients (9%) met the composite medication indicator: being prescribed — or documented as contraindicated/intolerant to — all four classes of GDMT. The abstract attributes much of this shortfall to subsidy eligibility rules: 92 patients (67% of the HFrEF subgroup) were reported as ineligible for subsidy for sodium glucose co-transporter-2 inhibitors (SGLT2is). This ineligibility materially reduced the number of patients who could meet the four-class composite indicator.
Prescription rates for the other GDMT drug classes were described as suboptimal by the investigators, but the abstract does not supply class-specific prescription rates, dosing details, titration strategies, or documentation practices for contraindications and intolerances. The absence of those granular data limits assessment of whether low composite attainment reflected underprescribing, guideline complexity, documentation gaps, or other system-level barriers.
Investigators concluded that a substantial gap exists between guideline recommendations for heart failure care and observed practice in this pilot cohort. Following completion of the pilot, the study team reported that performance indicators have been established and that the registry has continued; the abstract does not detail the specific performance metrics chosen, nor does it describe planned reporting cadence, quality-improvement interventions, or longer-term clinical outcomes to be monitored.
Limitations and open items reported in the abstract include: the report does not present detailed demographic or comorbidity data for the cohort; class-specific GDMT prescription percentages and dosing or titration information are not provided; reasons for missing LVEF assessments in 19% of patients are not reported; and the future operational plan for the registry beyond indicating that performance indicators were established is not described. These gaps define immediate questions for follow-up analyses: what were the drivers of suboptimal prescriptions for non-SGLT2i GDMT classes, how will registry-derived indicators be used to change practice, and will future registry reports include longitudinal outcomes such as rehospitalisation or mortality.
The abstract offers a transparent snapshot of the pilot's principal findings and feasibility metrics, while leaving detailed prescribing patterns, implementation strategies for quality improvement, and longer-term outcomes to subsequent reports. The study team observed actionable shortfalls in care delivery; specific next steps and detailed registry outputs were not provided in the abstract and therefore could not be summarised here.